Australian scientists have discovered that regular fish oil has the potential to break down superbugs' ability to become resistant to antibiotics.
Rediroom provides an instant and mobile patient isolation solution increasing bed management options for Infection Prevention Teams and Bed Flow Managers.
Novavax's COVID-19 vaccine demonstrated 100% protection against moderate and severe disease, with 90.4% efficacy overall, in the PREVENT-19 Phase 3 trial.
GSK Australia has announced that a new vaccine to help protect against shingles in adults aged 50 years and older is now available on the private market in Australia.
Robotic floor cleaning can support enhanced cleaning performance and protocols, helping healthcare organisations unlock consistent cleanliness and operational efficiencies.
Australian and US researchers have developed an experimental direct-acting antiviral therapy to treat COVID-19.
UNSW's Kirby Institute has used mathematical modelling to test the effectiveness of different vaccination strategies for controlling the COVID-19 pandemic.
In the washroom, Australians are most concerned about their co-workers not washing their hands, touching door handles and taps, and the cleanliness of the air.
A Singapore–Australia travel bubble may be possible with fast and accurate ways to test and clear incoming visitors.
The Society of Hospital Pharmacists of Australia and Royal Australian College of General Practitioners have welcomed changes to the COVID-19 vaccine rollout.
MediSound partnered with French company Germitec to offer Australia a system that can high-level disinfect an ultrasound probe and cable in 90 seconds.
Installation of UV Angel at Smile One Services raised the bar for the standard of safety for staff and patients, and increased revenue by 25% compared with pre-pandemic business.
The coating could be used on wound dressings and implants to prevent and treat potentially deadly bacterial and fungal infections.
Avalon Robotics — a joint venture between Avalon SteriTech and SoftBank Robotics Group — will focus on developing innovative products and technologies that benefit public health and wellbeing.
The AstraZeneca COVID-19 vaccine will no longer be the preferred choice for Australians under the age of 50, due to rare but serious blood clotting side effects.